228 related articles for article (PubMed ID: 18056164)
1. Selective inhibition of fatty acid synthase for lung cancer treatment.
Orita H; Coulter J; Lemmon C; Tully E; Vadlamudi A; Medghalchi SM; Kuhajda FP; Gabrielson E
Clin Cancer Res; 2007 Dec; 13(23):7139-45. PubMed ID: 18056164
[TBL] [Abstract][Full Text] [Related]
2. Fatty acid synthase inhibition activates AMP-activated protein kinase in SKOV3 human ovarian cancer cells.
Zhou W; Han WF; Landree LE; Thupari JN; Pinn ML; Bililign T; Kim EK; Vadlamudi A; Medghalchi SM; El Meskini R; Ronnett GV; Townsend CA; Kuhajda FP
Cancer Res; 2007 Apr; 67(7):2964-71. PubMed ID: 17409402
[TBL] [Abstract][Full Text] [Related]
3. Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression.
Pizer ES; Pflug BR; Bova GS; Han WF; Udan MS; Nelson JB
Prostate; 2001 May; 47(2):102-10. PubMed ID: 11340632
[TBL] [Abstract][Full Text] [Related]
4. Increased fatty acid synthase is a therapeutic target in mesothelioma.
Gabrielson EW; Pinn ML; Testa JR; Kuhajda FP
Clin Cancer Res; 2001 Jan; 7(1):153-7. PubMed ID: 11205903
[TBL] [Abstract][Full Text] [Related]
5. Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model.
Pflug BR; Pecher SM; Brink AW; Nelson JB; Foster BA
Prostate; 2003 Nov; 57(3):245-54. PubMed ID: 14518031
[TBL] [Abstract][Full Text] [Related]
6. Application of a flexible synthesis of (5R)-thiolactomycin to develop new inhibitors of type I fatty acid synthase.
McFadden JM; Medghalchi SM; Thupari JN; Pinn ML; Vadlamudi A; Miller KI; Kuhajda FP; Townsend CA
J Med Chem; 2005 Feb; 48(4):946-61. PubMed ID: 15715465
[TBL] [Abstract][Full Text] [Related]
7. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts.
Puri N; Khramtsov A; Ahmed S; Nallasura V; Hetzel JT; Jagadeeswaran R; Karczmar G; Salgia R
Cancer Res; 2007 Apr; 67(8):3529-34. PubMed ID: 17440059
[TBL] [Abstract][Full Text] [Related]
8. Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts.
Pizer ES; Thupari J; Han WF; Pinn ML; Chrest FJ; Frehywot GL; Townsend CA; Kuhajda FP
Cancer Res; 2000 Jan; 60(2):213-8. PubMed ID: 10667561
[TBL] [Abstract][Full Text] [Related]
9. Cyclooxygenase-2 inhibitor, nimesulide, improves radiation treatment against non-small cell lung cancer both in vitro and in vivo.
Grimes KR; Warren GW; Fang F; Xu Y; St Clair WH
Oncol Rep; 2006 Oct; 16(4):771-6. PubMed ID: 16969492
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of fatty acid synthase-dependent neoplastic lipogenesis as the mechanism of gamma-linolenic acid-induced toxicity to tumor cells: an extension to Nwankwo's hypothesis.
Menendez JA; Colomer R; Lupu R
Med Hypotheses; 2005; 64(2):337-41. PubMed ID: 15607568
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological inhibitor of fatty acid synthase suppresses growth and invasiveness of renal cancer cells.
Horiguchi A; Asano T; Asano T; Ito K; Sumitomo M; Hayakawa M
J Urol; 2008 Aug; 180(2):729-36. PubMed ID: 18555493
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models.
Zou Y; Fu H; Ghosh S; Farquhar D; Klostergaard J
Clin Cancer Res; 2004 Nov; 10(21):7382-91. PubMed ID: 15534115
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer.
Pizer ES; Wood FD; Heine HS; Romantsev FE; Pasternack GR; Kuhajda FP
Cancer Res; 1996 Mar; 56(6):1189-93. PubMed ID: 8640795
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumour activity in non-small cell lung cancer models and toxicity profiles for novel ruthenium(II) based organo-metallic compounds.
Guichard SM; Else R; Reid E; Zeitlin B; Aird R; Muir M; Dodds M; Fiebig H; Sadler PJ; Jodrell DI
Biochem Pharmacol; 2006 Feb; 71(4):408-15. PubMed ID: 16360645
[TBL] [Abstract][Full Text] [Related]
15. Green tea catechin inhibits fatty acid synthase without stimulating carnitine palmitoyltransferase-1 or inducing weight loss in experimental animals.
Puig T; Relat J; Marrero PF; Haro D; Brunet J; Colomer R
Anticancer Res; 2008; 28(6A):3671-6. PubMed ID: 19189648
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models.
Suzuki T; Fujii A; Ohya J; Nakamura H; Fujita F; Koike M; Fujita M
Cancer Sci; 2009 Aug; 100(8):1526-31. PubMed ID: 19459856
[TBL] [Abstract][Full Text] [Related]
17. [Significance of fatty acid synthase expression in non-small cell lung cancer].
Wang Y; Zhang X; Tan W; Fu J; Zhang W
Zhonghua Zhong Liu Za Zhi; 2002 May; 24(3):271-3. PubMed ID: 12515624
[TBL] [Abstract][Full Text] [Related]
18. Malonyl-CoA decarboxylase inhibition is selectively cytotoxic to human breast cancer cells.
Zhou W; Tu Y; Simpson PJ; Kuhajda FP
Oncogene; 2009 Aug; 28(33):2979-87. PubMed ID: 19543323
[TBL] [Abstract][Full Text] [Related]
19. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
20. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
